Portola Pharmaceuticals Presents New In Vitro Data | PTLA Message Board Posts

Portola Pharmaceuticals, Inc.

  PTLA website

PTLA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  6372 of 6517  at  7/8/2019 8:46:44 PM  by

tjinvest


 In response to msg 6370 by  erniewerner
view thread

Re: Portola Pharmaceuticals Presents New In Vitro Data

To the extent people assumed KCentra to be
more effective
than this (like UpToDate guidelines), the PR is good news.  I always assumed KCentra did virtually nothing vs FXa inhibitors, so this isn't necessarily good news to me.

i.e. When life-threatening and high FXa inhibition levels, Andexxa is a lock.  What's needed is more and more expansion into less than absolute life-threatening situations.  But from this PR, we now know maybe 25% of the "potential Andexxa patients" have levels < 75 ng/ml, and might be effectively treated with KCentra.  That's a big chunk.  And I wonder what the FXa inhibition curve looks like at the tail end.  How quickly does it drop off from that reported median level of 94 ng/ml to a potential KCentra level below 75 ng/ml?  If only a few hours, then it could chip away even further.

Other potential factors???

- Maybe with NTP payments, the cost delta isn't a big enough to worry about?  I doubt this because many cases need more than a single dose, so the cost delta is not what I'd call small.

- If prepping Andexxa is a PITA and takes time anyway, you might just have more people sticking with KCentra as first-line, and Andexxa second line therapy.  Say you would've had to wait an hour for A prep, so you decide to just wait a couple hours for 75 ng/ml, then use KCentra.  Again, we're talking outside of life-threatening bleeds, high concentrations, etc).



"For example, in the ANNEXA-4 trial of Andexxa in Factor Xa inhibitor-treated patients with acute major bleeding, approximately 75% of the patients had anticoagulant concentrations above 75 ng/mL at the time of Andexxa reversal therapy."


 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 397
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
6373 Re: Portola Pharmaceuticals Presents New In Vitro Data JoeFlow 8 7/9/2019 7:01:14 AM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...